Form 4: RA Capital Management Increases Stake in Werewolf Therapeutics (HOWL) Through Open Market Purchases
SEC Form 4 Filing
RA Capital Management, a significant shareholder in Werewolf Therapeutics, has increased its holdings through a series of open market purchases between May 12 and May 14, 2025.
Summary
- RA Capital Management, L.P., along with related entities and individuals, has reported changes in their beneficial ownership of Werewolf Therapeutics, Inc. (HOWL) common stock.
- Between May 12 and May 14, 2025, RA Capital entities purchased a total of 536,426 shares of HOWL common stock through multiple transactions on the open market.
- The purchases were made at weighted average prices ranging from $0.82 to $0.99 per share.
- Following these transactions, RA Capital's total indirect beneficial ownership of Werewolf Therapeutics common stock increased to 6,237,482 shares for RA Capital Healthcare Fund, L.P. and 443,825 for RA Capital Nexus Fund II, L.P.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. RA Capital's increased investment suggests confidence, but the filing itself is simply a record of transactions.
Positives
- RA Capital Management's increased investment could be interpreted as a sign of confidence in Werewolf Therapeutics' future prospects.
Future Outlook
The document does not contain explicit forward-looking statements regarding Werewolf Therapeutics' future performance.
Industry Context
This filing reflects investment activity in the biotechnology sector, where companies like Werewolf Therapeutics are focused on developing novel therapies. Monitoring insider transactions can provide insights into investor sentiment and potential future performance.
Comparison to Industry Standards
- It's common for major shareholders in biotech companies to adjust their positions based on their assessment of the company's progress and market conditions.
- Similar filings can be observed for other biotech firms like Amgen (AMGN) or Gilead Sciences (GILD), where institutional investors regularly update their holdings.
Stakeholder Impact
- Shareholders may view RA Capital's increased stake as a positive signal.
- The transactions could influence market perception of Werewolf Therapeutics.
Key Dates
| Date | Description |
|---|---|
| 05/12/2025 | Initial transaction date for the purchase of common stock. |
| 05/13/2025 | Second transaction date for the purchase of common stock. |
| 05/14/2025 | Final transaction date for the purchase of common stock and date of filing. |
Keywords
Werewolf Therapeutics, HOWL, RA Capital Management, Beneficial Ownership, SEC Form 4, Stock Purchase, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.